GT Biopharma Inc. has announced a significant development regarding its Series L 10% Convertible Preferred Stock. The company reported that on September 17, 18, and 23, 2025, certain holders of this preferred stock provided a waiver to the Certificate of Designation, agreeing to forgo their rights to redemption as outlined in Section 10 of the document. This waiver represents a material modification to the rights of these security holders, allowing GT Biopharma greater flexibility in managing its financial obligations related to the Series L Preferred Stock.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-014684), on September 23, 2025, and is solely responsible for the information contained therein.